Genetic Variants Linked to CAR T-Cell Efficacy and Safety

Researchers have identified specific genetic variants that influence the efficacy and toxicity of CAR T-cell therapy in lymphoma patients. These findings suggest that a patient's unique genetic makeup plays a critical role in how they respond to personalized cancer immunotherapies.
Scientists have identified variants in three genes that influence both the efficacy of CAR T-cell therapy and the likelihood of severe side effects. Published today in Science Immunology , these findings represent a first step toward adopting a precision medicine approach in an increasingly used form of cancer immunotherapy.
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in